Friday, July 31, 2026

How Rasmotinib and PHI-501 Could Revolutionize Cancer Treatment: Insights from Bio Europe Spring 2026

Pharos iBio showcases its cancer treatments at Bio Europe Spring 2026, seeking global partnerships for Rasmotinib and PHI-501.

Alteogen and Biogen: A Game-Changing 200 Million USD License Deal for ALT-B4 Biopharmaceuticals

Alteogen partners with Biogen for exclusive licensing of subcutaneous biopharmaceuticals, potentially earning up to 549 million USD.

ABL209: The Promising Dual Antibody ADC Revolutionizing Cancer Treatment in 2026

ABL Bio's ABL209 shows promising anti-cancer effects with broad safety in preclinical studies, advancing to Phase 1 trials in the U.S.

Tag: surprise appearance

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

No posts to display

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.